- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 30.04. | Parexel buys Vitrana to boost patient safety toolkit | ||
| 30.04. | GLP-1s drive Lilly's Q1, but it's reticent on oral launch | ||
| 30.04. | Avalyn seeks $300m from its IPO | ||
| 30.04. | Teva makes its first M&A play in years, buying Emalex | ||
| 30.04. | NICE backs UCB drug as first uncontrolled gMG therapy | ||
| 30.04. | Norgine gets first EU approval for WHIM syndrome therapy | ||
| 29.04. | Chiesi signs $1.9bn deal to buy KalVista and its HAE drug | ||
| 29.04. | AZ will invest £300m in UK, says PM Keir Starmer | ||
| 29.04. | Amgen, AZ will pilot FDA's real-time clinical trial plan | ||
| 29.04. | AZ, Amgen will pilot FDA's real-time clinical trial plan | ||
| 29.04. | First-quarter sales strength buoys new GSK CEO Miels | ||
| 29.04. | UK study finds clue to rising cancer rates in younger people | ||
| 28.04. | Merck KGaA partners Remepy in PDURS-focused alliance | ||
| 28.04. | AI start-up Profluent nabs Lilly as first big pharma partner | ||
| 28.04. | Can Purdue finally get its bankruptcy plan over the line? | ||
| 28.04. | GSK eyes October FDA verdict on chronic hep B drug | ||
| 28.04. | Novartis shares fall as Entresto sales weaken | ||
| 28.04. | Boehringer/Zealand dual-acting drug causes 16.6% weight loss | ||
| 27.04. | Intellia files CRISPR drug after historic phase 3 readout | ||
| 27.04. | Lilly's M&A team strikes again with $2.3bn Ajax takeover | ||
| 27.04. | GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio | ||
| 27.04. | Lilly falls on slower start for Foundayo versus Wegovy | ||
| 27.04. | New NIHR-funded TRC for Parkinson's disease | ||
| 27.04. | Sun sets out $11.75bn takeover play for Organon | ||
| 24.04. | FDA grants three priority vouchers to psychedelics |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.